Report

The oncology based in-vivo CRO market was valued at USD 1.28 Billion in 2025 . It is poised to grow at a CAGR of 7.90% during the forecast period of 2026-2035, reaching USD 2.74 Billion by 2035 . The market is driven by the rising global cancer burden, increasing pharmaceutical outsourcing of preclinical CRO services, and the expanding adoption of advanced in-vivo oncology models for cancer drug development.

Key Market Trends and Insights

- Based on the indication, the solid tumors segment is expected to lead the market with more than 45% inthe historical period.
- By model, the patient-derived xenograft (PDX) segment is expected to lead the market in the forecast period.
- North America held nearly 49% market share in the historical period.

Market Size and Forecast

- Market Size (2025): USD 1.28 Billion
- Projected Market Size (2035): USD 2.74 Billion
- CAGR (2026-2035): 7.90%
- Largest Market in 2025: North America

Oncology Based In-Vivo CRO Market Overview

The oncology contract research organization (CRO) market refers to specialized companies that provide in vivo research services for cancer drug evaluation, leveraging living models to assess treatment efficacy, safety, and pharmacological properties. These services encompass preclinical CRO studies using animal models, including syngeneic tumor models, xenograft models, and patient-derived xenografts (PDX) to simulate human tumor biology. As per Expert Market Research (EMR), the market is poised to grow at a CAGR of 7.90% during the forecast period of 2026-2035). The growth is supported by rising pharmaceutical R&D outsourcing, expanding immuno-oncology CRO capabilities, and the development of personalized cancer therapies globally.

Oncology Based In-Vivo CRO Market Growth Drivers

Rising Global Cancer Burden to Accelerate the Market Value

The escalating global incidence of cancer is the primary driver of the oncology contract research organization market. According to the International Agency for Research on Cancer (IARC), cancer caused approximately 9.7 million deaths in 2022, with over 35 million new cancer cases predicted in 2050. This surge in cancer prevalence compels pharmaceutical and biotechnology companies to accelerate cancer drug development pipelines, increasing reliance on specialized preclinical CRO providers.

Oncology Based In-Vivo CRO Market Growth Trends

Several key trends in the market include the increasing adoption of advanced humanized in vivo platforms to accelerate oncology CRO capabilities.

Growing Advanced Humanized In-Vivo Platforms to Accelerate the Oncology CRO Capabilities and Enhance Market Growth

The increasing adoption of advanced humanized in-vivo models is emerging as a key trend in the oncology-based in-vivo CRO market, improving translational accuracy and drug development efficiency. In April 2025, Charles River Laboratories International, Inc. introduced enhanced platforms, including patient-derived xenograft models and tumoroids, to support oncology research. These innovations enable precise target identification and therapeutic evaluation, strengthening CRO service capabilities and driving sustained market growth.

Oncology Based In-Vivo CRO Market Segmentation

Market Breakup by Indication

- Blood Cancer
- Solid Tumors
- Other Indications

Market Breakup by Model

- Syngeneic
- Xenograft
- Patient Derived Xenograft (PDX)

Market Breakup by Region

- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa

Oncology Based In-Vivo CRO Market Share

Solid Tumors Segment to Lead the Market by Indication

The solid tumors segment is likely to have a major share in the market by indication, owing to the high prevalence of cancers such as breast, lung, colorectal, and prostate malignancies worldwide. These tumor types attract significant pharmaceutical investment in drug discovery. Xenograft models and patient-derived xenografts (PDX) are extensively deployed for solid tumor efficacy testing, making this segment the most resource-intensive and commercially significant for preclinical CRO providers.

Oncology Based In-Vivo CRO Market Analysis by Region

The regions included in the market are North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. Among these, North America is expected to witness substantial market share, driven by high cancer incidence, strong NIH funding, and concentration of leading preclinical CRO providers. Europe is also growing significantly, supported by active R&D investment and clinical trial activity. Asia Pacific is the fastest-growing region, propelled by cost advantages, expanding biotech ecosystems in China and India, and rising government support for oncology research.

Leading Players in the Oncology Based In-Vivo CRO Market

The key features of the market report include patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Crown Bioscience Inc.

Crown Bioscience Inc. is a global oncology contract research organization headquartered in San Diego, California, specializing in translational oncology and immuno-oncology. The company offers patient-derived xenograft (PDX) platforms and syngeneic tumor model services for cancer drug development. In 2023, it launched the OrganoidXplore service, enhancing preclinical oncology services for pharmaceutical partners.

Charles River Laboratories Inc.

Charles River Laboratories Inc. is a leading U.S.-based preclinical CRO offering end-to-end in-vivo oncology models including xenograft models and PDX platforms. The company serves global pharmaceutical and biotech firms across drug discovery and safety testing. In 2022, it introduced the OncoMouse PDX platform for high-throughput tumor modeling and integrated biomarker analytics, advancing cancer drug development efficiency.

ICON PLC

ICON PLC is an Ireland-based global clinical research organization providing comprehensive oncology contract research organization services across preclinical and clinical stages. The company supports cancer drug development through regulatory strategy, bioanalysis, and preclinical CRO capabilities. With operations across North America, Europe, and the Asia Pacific, ICON leverages its extensive oncology trial network to accelerate drug approvals globally.

Taconic Biosciences Inc.

Taconic Biosciences Inc. is a U.S.-based provider of genetically engineered mouse models and in-vivo oncology models, including syngeneic tumor models and humanized platforms for immuno-oncology CRO research. The company supports preclinical oncology services for pharmaceutical and academic clients globally, offering customized model development and breeding services.

Other key players include Covance Inc., Eurofins Scientific, EVOTEC, The Jackson Laboratory, Wuxi AppTec., and MI Bioresearch Inc.

Key Questions Answered in the Oncology Based In-Vivo CRO Market Report

- What was the oncology based in-vivo CRO market value in 2025?
- What is the oncology based in-vivo CRO market forecast outlook for 2026-2035?
- What major factors aid the demand for the oncology based in-vivo CRO market?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- What are the major oncology based in-vivo CRO market trends?
- Which indication is expected to dominate the market segment?
- Which model is projected to lead the market segment?
- Who are the key players in the oncology based in-vivo CRO market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?